Earnings and a potential kidney disease breakthrough

🚨 Less than 12 seats left...                                                                                                                                                                                                                                                                                                                                                                                                                 August 29, 2024 | [Read Online]( Earnings and a potential kidney disease breakthrough In partnership with Good day, 360! Here are our top investing ideas today. And special invitation to trade Jeff’s Pick of the Day with him this morning in the [Market Masters Room]( - his [Back to School Special]( ends tonight! Grab one of the 12 seats left! FOCUS LIST🔎 XRTX - Up over 50% in pre after highlights recent pioneering research indicating a role for genetic regulation of Xanthine Oxidase and therapeutic targeting of Aberrant Purine Metabolism AFRM - Up over 20% in pre after reporting better than expected earnings PSNY - Up over 5% in pre after reporting 82% growth in global deliveries *sponsored by 1440 Media The Daily Newsletter for Intellectually Curious Readers - We scour 100+ sources daily - Read by CEOs, scientists, business owners and more - 3.5 million subscribers [Sign up today!]( HOTLIST🔥 XRTX - Up over 50% in pre after highlights recent pioneering research indicating a role for genetic regulation of Xanthine Oxidase and therapeutic targeting of Aberrant Purine Metabolism XORTX Therapeutics Inc. (XRTX) is a late stage clinical pharmaceutical company that engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. In the pre-market this morning, the [company announced]( that recent peer-reviewed, independent, published research highlights that genetic factors are linked to the over-expression of xanthine oxidase (“XO”) and play a role in several diseases, including kidney disease. These ground-breaking findings further support the Company’s approach to treating kidney and other diseases by inhibiting XO. Findings included: ● Xanthine oxidase reported to modulate progression of chronic kidney disease, diabetic kidney disease, polycystic kidney disease, and other indications The stock traded up over 50% in the pre-market in reaction to the results. The first target for bulls is the pre-market high at $1.94. Beyond that, $2, $2.05, $2.15, $2.25, $2.40 and $2.60 come into play. Below $1.94, targets to the downside are $1.80, $1.70, $1.60, $1.50, $1.40, $1.30 and then a gap fill at $1.15. AFRM - Up over 20% in pre after reporting better than expected earnings Affirm Holdings, Inc. (AFRM) operates a platform for digital and mobile-first commerce in the United States, Canada, and internationally. The company's platform includes point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. In the after-hours yesterday, the [company reported]( Q4 financial results. Q4 EPS came in at a loss of $0.14 per share vs estimate of a loss of $0.45. This compares to a loss of $0.69 per share a year ago. Q4 revenues came in at $659.19 million for the quarter ended June 2024, surpassing estimates by 9.96%. This compares to year-ago revenues of $445.83 million. The stock traded up over 20% in the pre-market in reaction to the positive financial results. The first target for bulls is the pre-market high at $38.85. Beyond that, $40 and $44 come into play. Below $38.85, targets to the downside are $37, $36, $35.60, $35, $34, $33 and then a gap fill at $31.58. BACK TO SCHOOL SALE: Bullseye Unlimited Trade Live w/ Jeff Bishop 9:20-10:30am ET Tuesday's Trade Alert -> Netflix Calls *Note: Trading is hard, results not guaranteed and should not be expected to be replicated typically. What will the NEXT one be? Get on [this LIST]( and live trade it with Jeff – but don’t delay… Less than 12 Seats Remain at this Pricing! PSNY - Up over 5% in pre after reporting 82% growth in global deliveries Polestar Automotive Holding UK PLC (PSNY) manufactures and sells premium electric vehicles. The company was founded in 2017 and is headquartered in Gothenburg, Sweden. In the pre-market this morning, the [company published]( Q2 2024 financial results and reported 82% growth in global deliveries. Highlights include: 13,150 cars delivered in Q2 2024, up 82% compared to Q1 2024 30% improvement in inventory turnover driving working capital reduction with positive impact on cash flow Secured up to USD 300 million in additional external funding in August - Revenue decreased by USD 319.6 million or 26%, mainly due to lower global vehicle sales and higher discounts in a competitive market. - Operating loss decreased by USD 31.2 million or 6%, with lower revenue offset by cost management actions. The stock traded up over 5% in the pre-market in reaction to the financial results and increased deliveries. The one $1 area has acted as support and resistance yesterday and will be an important level to watch. Above it, targets to the upside are $1.05, $1.10, $1.13, $1.20 and $1.24. Below $1, targets to the downside are $0.97 a gap fill at $0.9450 and then $0.88. MARKET NEWS 📰 Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America [Terms of Service](